Department of Urology, Shanghai Tenth People's Hospital, Tongji University, Shanghai 200072, PR China.
Anhui Medical University Shanghai Clinical College, PR China.
Biomark Med. 2018 Dec;12(12):1347-1359. doi: 10.2217/bmm-2018-0229. Epub 2018 Dec 3.
It has become increasingly clear that the development of cancer, a multifactorial disease, cannot be explained by a single molecule or gene mutation. As a new discipline, metabolomics focuses on the body's metabolite changes, and attempts to find differences to explain the development of cancer; it has proven to be effective and credible. Metabolic studies of bladder cancer (BCa) lag behind those of other tumors. This review systematically outlines the specific process of metabolomics and the use of metabolomics in BCa studies in recent years. We have reviewed the in vitro cell line, bladder tumor tissue and biofluid (urine, plasma and serum) studies used in metabolomics analyses of BCa. The advantages and drawbacks of the use of different samples were compared. Based on the available studies, we have further described the aberrant metabolic pathways of BCa and have suggested some metabolites that may be potential biomarkers for BCa detection.
越来越明显的是，癌症是一种多因素疾病，不能仅用单个分子或基因突变来解释。作为一门新兴学科，代谢组学专注于人体代谢物的变化，并试图寻找差异来解释癌症的发生；事实证明，这是一种有效且可信的方法。膀胱癌（BCa）的代谢研究落后于其他肿瘤。本文系统地概述了代谢组学的具体过程以及近年来代谢组学在 BCa 研究中的应用。我们综述了用于膀胱癌代谢组学分析的体外细胞系、膀胱肿瘤组织和生物体液（尿液、血浆和血清）研究。比较了使用不同样本的优缺点。基于现有研究，我们进一步描述了膀胱癌的异常代谢途径，并提出了一些可能成为膀胱癌检测潜在生物标志物的代谢物。
